Trevi Therapeutics Financials
| TRVI Stock | USD 6.47 0.14 2.12% |
Trevi |
Trevi Therapeutics Stock Summary
Trevi Therapeutics competes with Cue Biopharma, AN2 Therapeutics, Bioatla, Spero Therapeutics, and Bolt Biotherapeutics. Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. Trevi Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 23 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US89532M1018 |
| CUSIP | 89532M101 |
| Location | Connecticut; U.S.A |
| Business Address | 195 Church Street, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.trevitherapeutics.com |
| Phone | 203 304 2499 |
| Currency | USD - US Dollar |
Trevi Therapeutics Key Financial Ratios
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.32 | ||||
| Target Price | 19.83 | ||||
| Beta | 0.91 |
Trevi Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Trevi Therapeutics's current stock value. Our valuation model uses many indicators to compare Trevi Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Trevi Therapeutics competition to find correlations between indicators driving Trevi Therapeutics's intrinsic value. More Info.Trevi Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Trevi Therapeutics' earnings, one of the primary drivers of an investment's value.Trevi Therapeutics Systematic Risk
Trevi Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Trevi Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on Trevi Therapeutics correlated with the market. If Beta is less than 0 Trevi Therapeutics generally moves in the opposite direction as compared to the market. If Trevi Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Trevi Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Trevi Therapeutics is generally in the same direction as the market. If Beta > 1 Trevi Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
About Trevi Therapeutics Financials
What exactly are Trevi Therapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Trevi Therapeutics' income statement, its balance sheet, and the statement of cash flows. Potential Trevi Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Trevi Therapeutics investors may use each financial statement separately, they are all related. The changes in Trevi Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Trevi Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Trevi Therapeutics March 22, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Trevi Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Trevi Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Trevi Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Trevi Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Trevi Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.32 | |||
| Information Ratio | 0.1572 | |||
| Maximum Drawdown | 44.27 | |||
| Value At Risk | (5.75) | |||
| Potential Upside | 7.11 |
Complementary Tools for Trevi Stock analysis
When running Trevi Therapeutics' price analysis, check to measure Trevi Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trevi Therapeutics is operating at the current time. Most of Trevi Therapeutics' value examination focuses on studying past and present price action to predict the probability of Trevi Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trevi Therapeutics' price. Additionally, you may evaluate how the addition of Trevi Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |